HDAC/JAK/BRD4-IN-1

HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent HDAC/JAK/BRD4 triple inhibitor. HDAC/JAK/BRD4-IN-1 inhibit cell growth and induces apoptosis in MDA-MB-231 cells, and shows anticancer activity in vivo[1].

Product Specifications

CAS Number

[2755325-84-7]

UNSPSC

12352005

Target

Apoptosis; Epigenetic Reader Domain; HDAC; JAK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hdac-jak-brd4-in-1.html

Concentration

10mM

Purity

95.07

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

ONC(C1=CC=C(C=C1)NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=O

Molecular Formula

C24H28N6O3

Molecular Weight

448.52

References & Citations

[1]Zhao C, et al. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer [published online ahead of print, 2023 Oct 5]. J Med Chem. 2023;10.1021/acs.jmedchem.3c01242.